Video
Author(s):
The development of new medications to help patients with plaque psoriasis seems to take steps forward on a daily basis. Results presented at a recent conference showed at least one could help provide much needed relief for this patient group.
The development of new medications to help patients with plaque psoriasis seems to take steps forward on a daily basis. Results presented at a recent conference showed at least one could help provide much needed relief for this patient group.
Kim Papp, MD, FAAD, one of the researchers involved described the potential benefits of a novel selective interleukin (IL)-23p19 antagonist monoclonal antibody for the treatment of plaque psoriasis during the American Academy of Dermatology's annual meeting in San Francisco.